Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;8(4):134-140.
doi: 10.1177/24755303231186405. Epub 2023 Jun 26.

Paradoxical Effects of Depression on Psoriatic Arthritis Outcomes in a Combined Psoriasis-Psoriatic Arthritis Center

Rebecca H Haberman  1 , Seungha Um  2 , Sydney Catron  1 , Alan Chen  2 , Eileen Lydon  1 , Malavikalakshmi Attur  1 , Andrea L Neimann  3 , Soumya Reddy  1 , Andrea Troxel  2 , Samrachana Adhikari  2 , Jose U Scher  1   4
Affiliations

Paradoxical Effects of Depression on Psoriatic Arthritis Outcomes in a Combined Psoriasis-Psoriatic Arthritis Center

Rebecca H Haberman et al. J Psoriasis Psoriatic Arthritis. 2023 Oct.

Abstract

Backgroud: Psoriatic arthritis (PsA) is a chronic, inflammatory arthritis that, when left untreated, can lead to erosions, deformities and decrease in quality of life. PsA is known to be associated with multiple comorbidities, including cardiovascular, metabolic and mental health syndromes, all of which can increase its overall morbidity and mortality.

Objective: To characterize a cohort of patients with PsA and understand the impact of depression on PsA outcome measures.

Methods: 527 consecutive patients with PsA were enrolled in an observational, longitudinal registry that followed them prospectively at standard of care visits. Demographics, medical history, medication use, and clinical exam were all recorded.

Results: Depression was reported in 22.8% of the population, anxiety in 18%, and attention deficit hyperactivity disorder in 4%. Depression was more common in female participants (P < .001). At baseline, individuals with PsA and concomitant depression had similar tender and swollen joint counts and RAPID3 compared to those without depression, and had lower body surface area affected by psoriasis (P = .04). At year one, all patients had improvement in clinical outcomes. However, patients with depression had a significantly higher tender joint count compared to those without depression (P = .001), despite similar swollen joint count and body surface area.

Conclusion: In patients with depression, there is a discrepancy between improvement in physician assessed measures and patient reported outcomes. These observations underscore the importance of addressing depression and psychological distress as part of PsA treatment outcomes and points towards the need to address residual pain through co-adjuvant approaches.

Keywords: depression; depression < comorbidity < psoriasis; pain; patient-reported outcome < psoriasis; psoriasis; psoriatic arthritis; treatment outcomes < treatment < psoriasis.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: RHH has served as a consultant for Janssen and UCB. ALN declares that she has served as a consultant for Janssen, UCB, AbbVie, BMS and her immediate family member owns shares of stock in J&J, Eli Lilly, AbbVie, and Pfizer. SR has served as a consultant for AbbVie/Abbott, Amgen, Novartis, Janssen, Pfizer. SA has received grants from Johnson and Johnson. JUS has served as a consultant for Janssen, Novartis, Pfizer, Sanofi, Amgen, UCB and AbbVie; and has received funding for investigator-initiated studies from Janssen and Pfizer.

Figures

Figure 1.
Figure 1.
Observed mean PsA outcomes at baseline, year 1, and year 2. Red represents patients with depression, blue represents patients without depression. *P < .05.
Figure 2.
Figure 2.
Model predicted means with 95% confidence bands (A), and predicted ratio ratios and estimated differences (B), adjusting for age, sex, race, comorbidities, and medication use.
See this image and copyright information in PMC

References

    1. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545-568. doi: 10.1016/j.rdc.2015.07.001 - DOI - PMC - PubMed
    1. Eder L, Cohen AD, Feldhamer I, Greenberg-Dotan S, Batat E, Zisman D. The epidemiology of psoriatic arthritis in Israel - a population-based study. Arthritis Res Ther. 2018;20(1):3. doi: 10.1186/s13075-017-1497-4 - DOI - PMC - PubMed
    1. Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):242-248. doi: 10.1016/j.jaad.2015.05.001 - DOI - PubMed
    1. Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045-1050. doi: 10.1136/annrheumdis-2013-204858 - DOI - PubMed
    1. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study. Ann Rheum Dis. 2015;74(2):326-332. doi: 10.1136/annrheumdis-2014-205675 - DOI - PMC - PubMed

LinkOut - more resources